Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 11, 2013
Distillery Therapeutics

Indication: Cancer

BioCentury | Apr 11, 2013
Cover Story

RET, set, go

BioCentury | Aug 6, 2012
Clinical News

Cabozantinib: Phase II started

BioCentury | Mar 1, 2012
Cover Story

REThinking lung cancer

BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Cancer

Items per page:
1 - 5 of 5